SK Biopharmaceuticals IPO Tabbed to Raise $850 Million

A South Korean pharmaceutical company plans to go public next month in an offering aimed at raising $850 million. The initial public offering comes on the heels of the Food and Drug Administration's approval of the company's epilepsy drug.